Şunu aradınız:: bevacizumab (İngilizce - Hollandaca)

bevacizumab
bevacizumab

xelox+ bevacizumab
xelox+ bevacizumab

bevacizumab (n=699)
bevacizumab (n=699)

placebo or bevacizumab
1,05 (0,94; 1,18)

folfox-4 + bevacizumab
bevacizumab

bevacizumab 25 mg per ml.
bevacizumab 25 mg per ml.

xelox or xelox+ bevacizumab
xelox of

each vial contains 100 mg bevacizumab.
elke flacon bevat 100 mg bevacizumab.

- the active substance is bevacizumab.
- de werkzame stof is bevacizumab.

patients with prior bevacizumab (n (%))
aantal met risico

ct+bv arm (chemotherapy plus bevacizumab):
ct+bv-arm (chemotherapie plus bevacizumab):

combination of bevacizumab and sunitinib malate
combinatie van bevacizumab en sunitinibmalaat

patients with no prior bevacizumab (n (%))
aantal sterfgevallen, n (%)

each 16 ml vial contains 400 mg of bevacizumab.
elke 16 ml flacon bevat 400 mg bevacizumab.

effect of antineoplastic agents on bevacizumab pharmacokinetics
het effect van antineoplastische middelen op de farmacokinetiek van bevacizumab

vectibix in combination with bevacizumab and chemotherapy regimens
vectibix in combinatie met bevacizumab en chemotherapieregimes

each ml of concentrate contains 25 mg of bevacizumab*.
elke ml concentraat bevat 25 mg bevacizumab*.

egfr monoclonal antibodies in combination with bevacizumab chemotherapy regimens
egfr monoklonale antilichamen in combinatie met bevacizumab-chemotherapieregimes

patients with prior bevacizumab excluding adjuvant only (n (%))
patiënten met vroeger gebruik van bevacizumab (n (%))

effect of bevacizumab on the pharmacokinetics of other antineoplastic agents
het effect van bevacizumab op de farmacokinetiek van andere antineoplastische middelen